Artificial Intelligence (AI) applications are being used to detect high-risk conditions, in surgery and to improve customer healthcare. In the Middle E...

Read More

Students returning to in-person learning after months of lockdowns face a new set of mental health challenges that only compound COVID-19’s existing toll. RGA's Diana Bosworth discusses the important role life and health insurers have to play in addressing this issue.&n... Read More

As insurers shift to incorporate new and alternative data sources, underwriters are taking on more specialized skills. In On the Risk, RGA data strategist Jordan Durlester and underwriter Jacqueline Waas&...

Read More

In July 2021, the CDC grabbed headlines when it announced that life expectancy in the U.S. had fallen from 78.8 years in 2019 to 77.3 years in 2020, the largest one-year drop since World War II. But what does that mean for life insurers? 

Read More

Curious about RGA’s global survey results?  Read More

Curious about RGA’s global survey results?  Read More

RGA fraud experts from a range of disciplines share their insights on the ever-evolving COVID-19 crisis and its impact on life and health insurance fraud. 

Read More

To innovate, insurers must marry a deeper understanding of how consumers make decisions with sophisticated product development based on the principles of behavioral science. RGA's customer research in Asia reveals surprising insights about the most successful insur... Read More

RGA's Hilary Henly, FCII, Global Medical Researcher, reviews pharmacogenomics, a fast-expanding and vitally important component in the field of precision medicine, in ReFlections. She makes the case that if genomic information is routinely available in a per...

Read More

It's an exciting time in the evolution of the understanding and management of multiple sclerosis. In this issue of ReFlections, Dr. Heather Lund, Regional Chief Medical Officer, Asia, offers an extensive and detailed piece providing much of the latest research ... Read More

As the world continues to battle COVID-19 and emerging variants of the SARS-CoV-2 virus, the life and health insurance industry finds itself both reviewing lessons learned and preparing for what will happen next. (Re)insurers’ ability to estimate COVID-19’s current a...

Read More

The long-term impacts of the COVID-19 pandemic on product innovation and development strategies are yet to be determined, but RGA's Dan Lyons suggests that a few major changes may remain and even become more common.
Read More

Review reactive thrombocytosis, explore multiple sclerosis, and understand pharmacogenomics in this issue.


Read More

Retirees need the reassurance a steady stream of income provides, argues RGA's Diana Bosworth. She tours an increasingly vibrant product development landscape oriented around encouraging financial wellness in retirement.  Read More

Research shows that timely, efficient, accurate, and fair claims settlements can strengthen the customer relationship in profound ways. On the other hand, underinvestment in claims can result in real reputational damage. RGA makes the case for claims innovation.  Read More

Curious about RGA's medical insights?  Contact us to learn m...

Read More

China is committed to making quality healthcare affordable and accessible to its residents, however it faces substantial challenges. RGA's Dipali Jawalkar provides an overview of China's health infrastructure, technology's impact on insurance product innovation,...

Read More

How will the COVID-19 pandemic impact life and health insurance distribution and sales in the long term? Peter Rodes and Eva Goldstein of RGAX, the transformation engine of RGA, discuss the key drivers of insurance's accelerated convergence. Read More

Curious about RGA’s global survey results? 

Read More

Aducanumab (Aduhelm^TM), a new drug designed to treat Alzheimer's disease was approved by the FDA on June 7, 2021. RGA's Dr. Dave Rengachary discusses what this means for insurance, as well as the controversies around it.

Read More